Send to

Choose Destination
Vaccine. 2006 Feb 20;24(8):1073-80. Epub 2005 Sep 20.

A novel synthetic adjuvant effectively enhances the immunogenicity of the influenza vaccine.

Author information

Instituto de Investigaciones Biomédicas, A.P. 70228, Ciudad Universitaria, 04510 México, D.F., México.


Influenza vaccination is a key intervention to reduce morbidity and mortality provoked by this disease. To date, the challenge of improving its efficacy remains unmet. The immunogenic synthetic peptide GK1 from Taenia crassiceps cysticerci was tested herein in its capacity as adjuvant, co-administered with the inactivated anti-influenza vaccine before and after challenge with influenza virus in both young and aged mice. Co-administration of GK1 with the influenza vaccine increased levels of anti-influenza antibodies in aged mice before and after infection, reduced the local inflammation that accompanied influenza vaccination itself and favored virus clearance after infection in both young and aged mice.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center